Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 52M | 10.5% |
| Gross Profit | 35M | 20.6% |
| Cost of Revenue | 17M | 5.9% |
| Operating expense | 65M | 2.9% |
| Net Income | -30M | 11.4% |
| EBITDA | -30M | 12.5% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 511M | 5.3% |
| Total Liabilities | 321M | 4.8% |
| Total Equity | 190M | 6.1% |
| Shares Outstanding | 149M | 1.4% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -28M | 128% |
| Cash from financing | 5.5M | 4192.1% |
EPS
Financial Highlights for Adaptive Biotechnologies in Q1 '25
Adaptive Biotechnologies reported a revenue of 52M, which is a 10.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 35M, marking a 20.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 17M, a -5.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 65M, showing a 2.9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -30M, showing a 11.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -30M, showing a -12.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Adaptive Biotechnologies with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
